NLRP3 Recombinant Rabbit mAb (S-2613-140)
NACHT,LRR and PYD domains-containing protein 3,Cold autoinflammatory syndrome 1 protein homolog,Cryopyrin,Mast cell maturation-associated-inducible protein 1,PYRIN-containing APAF1-like protein 1,Cias1,Mmig1,Nalp3,Pypaf1,Nlrp3
分享产品介绍 FAQs 评论(0)
宿主来源
Rabbit抗原名称
NLRP3分子别名
NACHT, LRR and PYD domains-containing protein 3; Cold autoinflammatory syndrome 1 protein homolog; Cryopyrin; Mast cell maturation-associated-inducible protein 1; PYRIN-containing APAF1-like protein 1; Cias1; Mmig1; Nalp3; Pypaf1; Nlrp3免疫原
Recombinant Protein细胞定位
Cytoskeleton, Nucleus, Secreted, Mitochondrion, Cytoplasm, Endoplasmic reticulumAccession
Q8R4B8克隆号
S-2613-140抗体类型
Recombinant mAb抗体同种型
IgG反应种属 ?
Ms阳性样本
J774A.1, RAW264.7纯化方式
Protein A浓度
0.5 mg/ml标记
Unconjugated性状
Liquid缓冲体系
PBS, 40% Glycerol, 0.05% BSA, 0.03% Proclin 300
储存条件
12 months from date of receipt / reconstitution, -20 °C as supplied
应用
WB
稀释度
应用 稀释度 推荐种属 WB 1:1000 Ms
NLRP3 (NOD-, LRR- and pyrin domain-containing protein 3) is a ~118 kDa cytosolic pattern-recognition receptor that assembles into the macromolecular “NLRP3 inflammasome” when confronted by a structurally diverse set of microbial toxins, RNA viruses, extracellular ATP, crystalline substances or metabolic danger signals; upon activation NLRP3 nucleates the adaptor ASC and pro-caspase-1 filaments, driving caspase-1–mediated proteolytic maturation of interleukin-1β/18 and gasdermin D, which triggers pyroptotic cell death and amplifies systemic inflammation, thereby placing NLRP3 at the hub of innate immunity, autoinflammatory syndromes and chronic metabolic disorders such as gout, atherosclerosis, Alzheimer’s disease and type-2 diabetes.
免疫印迹
WB result of NLRP3 Recombinant Rabbit mAb
Primary antibody: NLRP3 Recombinant Rabbit mAb at 1/1000 dilution
Lane 1: J774A.1 whole cell lysate 20 µg
Lane 2: RAW264.7 whole cell lysate 20 µg
Secondary antibody: Goat Anti-rabbit IgG, (H+L), HRP conjugated at 1/10000 dilution
Predicted MW: 118 kDa
Observed MW: 118 kDa
FAQs
我们一般不推荐客户回收利用抗体。 因为抗体使用之后缓冲体系已经发生改变，不同客户在回收抗体的保存条件上也会有差异，所以抗体回收使用效果无法保证。另外，我们对一批抗体回收验证测试，测试结果显示不同抗体可回收次数不同，一般效价越高的抗体，可重复使用的次数越多，客户可根据实验情况来确定
评论(0)